Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Evolutions in classification, etiopathogenesis, assessment and management

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 16-23

  Mahr, Alfred ^a   Moosig, Frank ^b   Neumann, Thomas ^c   Szczeklik, Wojciech ^d   Taillé, Camille ^e   Vaglio, Augusto ^f   Zwerina, Jochen ^g  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e BICHAT HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g HANUSCH HOSPITAL   (Austria)

Author keywords

ANCA; ChurgStrauss; eosinophilic granulomatosis with polyangiitis; epidemiology; pathogenesis; pathology; therapy

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EOTAXIN 3; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G4; INTERLEUKIN 25; MEPOLIZUMAB; METHOTREXATE; RITUXIMAB;

ASTHMA; CHURG STRAUSS SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; EOSINOPHILIC LEUKEMIA; GENETIC ASSOCIATION; HEART DISEASE; HUMAN; HYPER IMMUNOGLOBULIN G4 SYNDROME; HYPEREOSINOPHILIC SYNDROME; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOPATHOGENESIS; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; THORAX RADIOGRAPHY; WEGENER GRANULOMATOSIS;

ASTHMA; BIOLOGICAL MARKERS; CHURG-STRAUSS SYNDROME; DIAGNOSIS, DIFFERENTIAL; GLUCOCORTICOIDS; HUMANS; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; TERMINOLOGY AS TOPIC;

EID: 84890164920     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000015     Document Type: Review

References (66)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11.
2. Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45-49.
3. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130:607-612; e9.
4. Jeong YJ, Kim KI, Seo IJ, et al. Eosinophilic lung diseases: A clinical, radiologic, and pathologic overview. Radiographics 2007; 27:617-637; discussion 37- 9.
5. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65:270-281.
6. Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): Monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72:1011-1017.
7. Sinico RA, Bottero P, Guillevin L. Antineutrophil cytoplasmic autoantibodies and clinical phenotype in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2012; 130:1440; author reply -1.
8. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192.
9. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632-638.
10. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926-2935.
11. Cordier JF, Cottin V, Guillevin L, et al. L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Presse Med 2013; 42:507-510.
12. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094-1100.
13. Khoury P, Zagallo P, Talar-Williams C, et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 2012; 67:1149-1156.
14. Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: Vasculitides with frequent lung involvement. Semin Respir Crit Care Med 2011; 32:264-273.
15. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011; 50:1916-1920.
16. Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007; 56:3159-3166.
17. Wieczorek S, Hellmich B, Gross WL, Epplen JT. Associations of Churg- Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: Comment on the article by Vaglio et al. Arthritis Rheum 2008; 58:329-330.
18. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf 2007; 16:620-626.
19. Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: A case-crossover study. Thorax 2008; 63:677-682.
20. Kostianovsky A, Charles P, Alves JF, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: A prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012; 30:S83-S89.
21. Muschen M, Warskulat U, Perniok A, et al. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 1999; 155:915-925.
22. Kiene M, Csernok E, Muller A, et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001; 44:469-473.
23. Dallos T, Heiland GR, Strehl J, et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum 2010; 62:3496- 3503.
24. Jakiela B, Sanak M, Szczeklik W, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2011; 29:S23-S34.
25. Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47:1104- 1105.
26. Josselin-Mahr L, Werbrouck-Chiraux A, Garderet L, Cabane J. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: Evidence for the pathogenic role of a tyrosine kinase? Rheumatology (Oxford) . [Epub ahead of print]
27. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27:277-301.
28. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14:1284-1293.
29. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26-37.
30. Healy B, Bibby S, Steele R, et al. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol 2013; 131:571-576; e1-6.
31. Szczeklik W, Jakiela B, Adamek D, Musial J. Cutting edge issues in the Churg- Strauss syndrome. Clin Rev Allergy Immunol 2013; 44:39-50.
32. Jennette JC, Falk RJ. The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol 2007; 25:S52-S56.
33. Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999; 122 (Pt 3):427-439.
34. Chen KR, Sakamoto M, Ikemoto K, et al. Granulomatous arteritis in cutaneous lesions of Churg-Strauss syndrome. J Cutan Pathol 2007; 34:330-337.
35. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47:770-779.
36. Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: Update on pathophysiology and treatment. Curr Opin Rheumatol 2012; 24:24-30.
37. Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): State of the art. Allergy 2013; 68:261-273.
38. Szczeklik W, Sokolowska BM, Zuk J, et al. The course of asthma in Churg- Strauss syndrome. J Asthma 2011; 48:183-187.
39. Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy 2009; 64:589-595.
40. Bottero P, Bonini M, Vecchio F, et al. The common allergens in the Churg- Strauss syndrome. Allergy 2007; 62:1288-1294.
41. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-360.
42. Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol 2013; 132:336-341.
43. Szczeklik W, Sokolowska B, Mastalerz L, et al. Pulmonary findings in Churg- Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol 2010; 29:1127-1134.
44. Furuiye M, Yoshimura N, Kobayashi A, et al. Churg-Strauss syndrome versus chronic eosinophilic pneumonia on high-resolution computed tomographic findings. J Comput Assist Tomogr 2010; 34:19-22.
45. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136:1521-1528.
46. Szczeklik W, Grzanka P, Mastalerz L, et al. Lung involvement in Churg-Strauss syndrome as related to the activity of the disease. Allergy 2010; 65:1484- 1485.
47. Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg- Strauss syndrome: Impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236-243.
48. Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: A retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84:323-330.
49. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19-27.
50. Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg- Strauss syndrome. Arthritis Rheum 2010; 62:627-634.
51. Hansch A, Pfeil A, Rzanny R, et al. First-pass myocardial perfusion abnormalities in Churg-Strauss syndrome with cardiac involvement. Int J Cardiovasc Imaging 2009; 25:501-510.
52. Szczeklik W, Miszalski-Jamka T, Mastalerz L, et al. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J 2011; 75:649-655.
53. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92:1173- 1179.
54. Schmitt WH, Linder R, Reinhold-Keller E, Gross WL. Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network. Arthritis Rheum 2001; 44:1887- 1896.
55. Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 2012; 71:390-393.
56. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366:539-551.
57. Perez Alamino R, Martinez C, Espinoza LR. IgG4-associated vasculitis. Curr Rheumatol Rep 2013; 15:348.
58. Terrier B, Bieche I, Maisonobe T, et al. Interleukin-25: A cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 2010; 116:4523-4531.
59. Zwerina J, Bach C, Martorana D, et al. Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study. Rheumatology (Oxford) 2011; 50:1823- 1827.
60. Guilpain P, Auclair JF, Tamby MC, et al. Serum eosinophil cationic protein: A marker of disease activity in Churg-Strauss syndrome. Ann N Y Acad Sci 2007; 1107:392-399.
61. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
62. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17-28.
63. Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92:80-87.
64. Hot A, Guerry MJ, Smith R, et al. A multicenter survey of rituximab for eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Presse Me'd 2013; 42:698 (abstract
65. Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125:1336-1343.
66. Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155:341- 343.